author-photo

Enrique Gallardo Diaz

Autonomous University of Barcelona

25

Papers

43

Citations

Citation Trend

Filter By

Papers (17) Sort By

Journal Conference Others

Cost-effectiveness of apixaban versus other direct oral anticoagulants and low-molecular-weight-heparins for cancer associated venous thromboembolism in Spain.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated safety analysis.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Effect of concurrent proton pump inhibitors (PPI) use in patients (pts) treated with immune checkpoint inhibitors (ICI) for metastatic urothelial carcinoma (mUC).

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Cabazitaxel versus enzalutamide/abiraterone in CARD eligible mCRPC patients with or without germline HRR defects.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
ECO Experts’ consensus on establishing renal cancer healthcare quality measures in Spain.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
The role of previous radical local treatment (RLT) on the outcome of immune checkpoint inhibitors (ICI) in patients (pts) with metastatic urothelial carcinoma (mUC).

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
A randomized phase II study with ilixadencel, a cell-based immune primer, plus sunitinib versus sunitinib alone in synchronous metastatic renal cell carcinoma.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (6)
A phase II multicenter biomarker trial to study the predictive value of TMPRSS2-ERG before enzalutamide treatment in chemo-naïve metastatic castration-resistant prostate cancer.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
SPAZO2 (SOGUG): Outcomes of patients treated with pazopanib as first line in mRC according to gender in real world.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Phase II trial of cabazitaxel in patients with advanced or metastatic transitional cell carcinoma of the urothelial tract who have progressed within less than 12 months after cisplatin-based chemotherapy: A Spanish Oncology Genitourinary Group (SOGUG) study.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)